Neoprobe (NEOP +4.8%) shares are higher today after submitting a new drug application to the FDA...

|By:, SA News Editor

Neoprobe (NEOP +4.8%) shares are higher today after submitting a new drug application to the FDA for its cancer detection platform Lymphoseek. The company seeks clearance to market it for use in surgical oncology procedures.